Richard P Slaughter Associates Inc Acquires Shares of 2,005 Eli Lilly and Company (NYSE:LLY)

Richard P Slaughter Associates Inc bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,005 shares of the company's stock, valued at approximately $1,656,000.

Other large investors have also bought and sold shares of the company. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $43,000. FPC Investment Advisory Inc. increased its position in shares of Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at $48,000. Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $50,000. Finally, Capital A Wealth Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $63,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $0.71 during mid-day trading on Thursday, reaching $765.13. 3,632,853 shares of the company's stock traded hands, compared to its average volume of 3,644,547. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a market capitalization of $725.14 billion, a P/E ratio of 65.34, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The business's 50-day moving average price is $772.75 and its 200-day moving average price is $799.41. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue was up 45.2% on a year-over-year basis. During the same period last year, the business earned $2.58 earnings per share. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company's payout ratio is presently 48.82%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.